LongBio Pharma Lists on Hong Kong Stock Exchange: A Leader in Allergic and Autoimmune Disease Innovation in China

LongBio Pharma, a leading innovative drug developer for allergic and autoimmune diseases in China, recently listed on the Hong Kong Stock Exchange. The company issued its shares at HK$96.06 per share and opened at HK$144.30 per share, boasting a market capitalization of HK$10.7 billion. Qiming Venture Partners, a major investor, had a 4.27 percent stake in LongBio Pharma before the IPO, making it one of the major institutional investors. Founded in 2020, LongBio Pharma focuses on in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases. The founding team of LongBio Pharma, including Dr. Sun Naichao and Dr. Liu…